東陽光(600673.SH):擬以9.10億元購買廣藥5.0966%股權
格隆匯3月14日丨東陽光(600673.SH)公佈,公司於2021年12月實施重大資產出售暨關聯交易事項,出售公司所持有的宜昌東陽光長江藥業股份有限公司(簡稱“東陽光藥”)51.41%股權,公司控股股東深圳市東陽光實業發展有限公司(簡稱“深圳東陽光實業”或“控股股東”)就保護上市公司利益及延續其於2021年3月變更承諾相關安排等事項的考慮出具了承諾,給予公司未來向其及/或其指定的第三方購買廣東東陽光藥業有限公司(簡稱“廣藥”或“標的公司”)相應股權的權利(具體請見公司於2021年12月11發佈的《東陽光重大資產出售暨關聯交易報吿書(草案)(修訂稿)》)。
據此,公司擬行使相關權利,以9.10億元人民幣購買深圳東陽光實業持有的廣藥1425.13萬元註冊資本,佔廣藥股權比例為5.0966%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.